A Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Anti-PD-1 Antibody (HLX10) in Combination With Avastin Biosimilar (HLX04) in Patients With Advanced Solid Tumors
Clinical trial NCT03757936 · UNKNOWN
Trial details
- NCT number
- NCT03757936
- Sponsor
- Shanghai Henlius Biotech
- Status
- UNKNOWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2018-11-27
- Primary completion
- 2019-09-27
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.